Tag Archives: Cinqair

March, 2016

  • 24 March

    Teva’s Cinqair Granted FDA Approval for Treatment of Severe Asthma

    JERUSALEM–(BUSINESS WIRE)–Mar. 23, 2016– Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration(FDA) has approved CINQAIR® (reslizumab) Injection, an interleukin 5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with …